·ÇÎüÑÌÕß,nonsmokersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ï¸Ö§Æø¹Ü·ÎÅÝ/²¡Àíѧ,bronchiolo-alveolar/patholÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºËÌǺËÜÕËáÀà,ribonucleotidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÃÏ¢·ÅÁÆ,RadiotheropyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¢óÆÚNSCLC,NSCLCÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯µ°°×øD(CathD),cathDÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
32P-½ºÌå,32P-colloidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
GGTase-I»ùÒò,GGTase-IÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
FTase»ùÒò,FTaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó°ÏñÒýµ¼·ÅÁÆ,IGRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°±ëÄøN/CD13,APN/CD13Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±£·ÎÌÀ,baofeitangtherapymethodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
5-µªÍÑÑõ°ûÜÕ,5-aza-2'-deoxyeytidineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°±»ùÄ©¶ËëÄ,N-telopeptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÍÌ·ÖÑ¡,EndosomesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Rad51µ°°×,Rad51Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×é°·-ßÅßáÃÀÐÁ,His-INÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ª·ÇÌæÄá(Ò×Èðɳ),Gefitinib(Iressa)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ÂÈøÆæÏÙ²¡¶¾ÊÜÌå(CAR),CD46Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç×ÓÆø¹Ü¾µ,electrobronchoscopeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡Áö/·Î,Leiomyoma/lungÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡Áö/×Ó¹¬,Leiomyoma/uterusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ß²·ÔÄ·ÄÆ,PHOTOFRINÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯ÁÆÏà¹ØÐÔ°×ϸ°û¼õÉÙ,CILÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
131I-Ö×Áöϸ°ûºËÈËÊóǶºÏµ¥¿Ë¡¿¹Ìå,131I-chTNTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Á-°ëÈéÌÇ»ù,¦Á-galactosyl(¦Á-gal)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
pT1ÆÚ,pT1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
18·úÍÑÑõÆÏÌÑÌÇ,18fluorodeoxylucoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µÍÉøÎÂÈÈ»¯ÁÆ,Hyperthermo-chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¼Â³Éú,brucineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CD44µ¥¿¹,CD44McAbÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È¥ÕûºÏËØ-½ðÊôµ°°×ø8,ADAM8Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
GP·½°¸»¯ÁÆ,GPchemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÖʽðÊôµ°°×ø2(MMP-2),matrixMetalloproteinase-2(MMP-2)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
E¸Æð¤¸½µ°°×,E-cadherineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ»µ¨×ÓÈéÓÍ×¢ÉäÒº,Ya-Dan-ZiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Wip1»ùÒò,Wip1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö´ÎÓ¦ÓÃ,dividedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÁÁ¿´¦·½(DP),dose-prescription(DP)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
º¬Äδﲬ,NedaplatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ªÎ÷Ëû±õ/˳²¬,Cisplatin/gemcitabineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ĥ¸½×ÅÐͱ¾ÌåA2,Ephrin-A2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢СRNA-21,miRNA-21Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼××´ÏÙÔËÔØµ°°×,TransthyretinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û×ÔÉí·Ö»¯¿¹Ô-1,CDA1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾ÖÔîÐÔÄ¥²£Á§Õ÷,GGOÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ABCE1»ùÒò,ABCE1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ĥϸ°û¹Ç¼ÜÁ¬½Óµ°°×,EzrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ôʼ/Õï¶Ï,Primitive/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Reprimo»ùÒò,ReprimoÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
tuberinµ°°×,TuberinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÑÒÄþ,FeiyanningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û½Çµ°°×19-mRNA,cytokeratin19-mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÀà×ÅÉ«ÐÔ¸ÉÆ¤²¡»ùÒòD,XPD/ERCC2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²ÝËᲬ/³¤´ºÈð±õ,L-OHP/NVBÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ÉÈÅËØ¼¤»î»ùÒò,ISGsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÆ¤Ï¸°ûÌØÒì·Ö×Ó-1,endocanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʳ¹Ü·ÅÉäËðÉË,EsophagustoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ͼÏñÅä×¼,image registrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÛ״ϸ°û,Squamous CellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍ×ªÒÆ,lymphatic metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áܰͽá×ªÒÆ,lymph node metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒýÎÄ·ÖÎö,citation analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö·ÖÆÚ,Neoplasm StagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇСϸ°û·Î°©,Non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÇÖÈó,Neoplasm invasivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ҽѧͼÏñÅä×¼,Medical image registrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Ö²¿¸´·¢,Local recurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÅàÑøµÄÖ×Áöϸ°û,cultured tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ°°×ÖÊP16,Protein P16Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýάÊÊÐηÅÁÆ,three-dimensional conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÄÍÒ©µ°°×,Lung resistance proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TNM·ÖÆÚ,TNM stagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СÁºÏ¸°û,trabecular meshwork cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇСϸ°û·Î/·ÅÉäÁÆ·¨,non-small cell lung/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Kai1»ùÒò,Kai1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
RUNX3»ùÒò,RUNX3 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÔ×ªÒÆ,brain metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¬Ä¤ÈâÁö,Synovial sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áܰ͹ÜÃܶÈ,Lymphatic vessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÇÄÜʶ±ð,intelligent recognitionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CD44v6µ°°×,CD44v6 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
p21wAF1,p21 WAF1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
KDRÆô¶¯×Ó,KDR promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢ÎÀÐÇÖØ¸´,Microsatellite repeatsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Àà°©Áö,carcinoid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ï¸Ö§Æø¹Ü·ÎÅݰ©,bronchioloalveolar carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Fhitµ°°×,Fhit proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
FisherÅбð·ÖÎö,Fisher discriminant analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÊÐηÅÉäÖÎÁÆ,conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢Áܰ͹ÜÃܶÈ,lymphatic microvessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
nm23-H1µ°°×,nm23-H1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒÖÖÆµ°°×ÖÊÀà,Tumor suppressor proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó²»¯ÐÔѪ¹ÜÁö,Sclerosing hemangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hMLH1»ùÒò,hMLH1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NP·½°¸,NP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ͬÆÚ·Å»¯ÁÆ,Concurrent chemoradiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÖ×Áö/·ÅÉäÉãÓ°Êõ,Lung Neoplasms/radiographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ki-67µ°°×,Ki-67 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Сϸ°û·Î,small cell lungÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|